Vigene Biosciences Opens State-Of-The-Art Headquarters in Rockville, MD
ROCKVILLE, Md., Jan. 29, 2020 /PRNewswire-PRWeb/ -- Vigene Biosciences, a pioneer in the viral gene delivery space, unveils its 71,000 square foot state-of-the-art global headquarters in Rockville, MD. The dedication of the 10 GMP suites including GMP viral vector suites and GMP plasmid suites across 3 campuses coincides with the announcement of a long-term strategic partnership with ASC Therapeutics, a California gene-therapy company.
An award-winning CDMO, Vigene's mission is to make gene therapy affordable. It provides viral vector-based gene delivery services and products for research and clinical applications. It strives to achieve this vision by streamlining virus production from early conceptual stages to commercial manufacturing.
The new facility, custom-built for Vigene, combines new manufacturing technologies and high-yield production cell lines with the rigorous quality of cGMP and BSL-2. The new headquarters firmly seals Vigene's commitment to revolutionize gene and cell therapy while rooted in Montgomery County, Maryland, USA.
Vigene is listed on Inc. 5000 fastest-growing private companies in America for 2019 and 2018, named the 2018 ACG Emerging Company of the Year, and is a finalist for Maryland Tech Council's Emerging tech company of the year award 2019 and 2018. It is one of the few gene therapy CDMO companies in the world which offers research grade, pre-IND, IND, and commercial grade viral vectors and plasmid DNAs.
Among the VIP attendees at the dedication: Ben Wu, CEO, Montgomery County Economic Development Corporation, Gina Hann, President of Batten Hope Foundation, and Dr. Suk See DeRavin, a gene therapy leader from NIH. Quotes and photos from the dedication are available.
About Vigene Biosciences: Vigene Biosciences, Inc is a leader in viral vector based gene delivery for both life science research, gene therapy and cell therapy purposes. Headquartered in Rockville, Maryland, Vigene offers plasmid, AAV, lentivirus, retrovirus and adenovirus based products and custom services. Vigene's mission is to make gene therapy affordable. Vigene offers IND-enabling and IND-supporting materials as well as FDA- and EMA-compliant commercial products for plasmid, AAV, lentivirus, retrovirus and adenovirus with proven technologies and track records. To learn more about Vigene Biosciences, please visit http://www.vigenebio.com
SOURCE Vigene Biosciences
